Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel Corp VCEL
$39.71
▲ +1.04%
(+$0.41)
⬆️ Above Yest. High
Open
$39.30
Prev Close
$39.30
Day Range
$38.74 – $39.80
52W Range
$28.95 – $49.32
Market Cap
$2.03B
P/E (TTM)
82.68
Beta
1.09
EPS (TTM)
$0.42
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1997-02-04 |
| Shares Out. | 51,070,000 |
| Website | vcel.com/ ↗ |
| Phone | 17349305555 |
| Employees | 398 |
| Revenue | $77.5M |
| Gross Profit | $56.4M |
| Net Income | $2.2M |
| Free Cash Flow | $61.7M |
| Total Assets | $502.9M |
| Total Liabilities | $132.8M |
| Equity | $370.0M |
About Vericel Corp
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Vericel Corp is a publicly traded company under the ticker symbol VCEL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)